NRX Pharmaceuticals, Inc. (NRXP): Gross Profit

Revenue minus cost of revenue for the same annual period and currency, computed by TickerFacts from the filed figures. The issuer may report gross profit or margin on a different basis.

Computed by TickerFacts from revenue minus cost of revenue. This may differ from the issuer's reported gross profit or margin; check the revenue and cost definitions.

$940.0K

Year ended 2025-12-31

$1.80M

Trailing 12 months to 2026-06-30

Period ended	Gross Profit	Change YoY	Source filing
2025-12-31	$940.0K	n/a	2026-03-23, From 2025-01-01

Gross Profit at similar companies

Companies with the same SEC industry code (Pharmaceutical Preparations), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

Company	Year ended	Gross Profit	Change YoY
NRX Pharmaceuticals, Inc. (NRXP)	2025-12-31	$940.0K	n/a
Cannapharmarx, Inc. (CPMD)	2025-12-31	-$2.08M	n/m
IGC Pharma, Inc. (IGC)	2025-03-31	$619.0K	-15.6%
Longeveron Inc. (LGVN)	2025-12-31	$803.0K	-57.4%
China SXT Pharmaceuticals, Inc. (SXTC)	2026-03-31	$248.7K	-32.3%
Bespoke Extracts, Inc. (BSPK)	2024-12-31	$452.9K	+32.0%
Bio Essence Corp (BIOE)	2025-12-31	$1.43M	+558.0%
Dare Bioscience, Inc. (DARE)	2025-12-31	$734.4K	n/a
60 Degrees Pharmaceuticals, Inc. (SXTP)	2025-12-31	$223.8K	+0.4%

Compare NRXP, CPMD, IGC, LGVN side by side · Screen every company in Pharmaceutical Preparations ↗